Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > .01 by next week

<< Previous

Bullboard Posts

Next >>

Comment by Bvukmanicon Feb 11, 2021 9:04pm

148 Views

Post# 32548618

RE:RE:RE:RE:RE:.01 by next week

Already been confirmed. I had only seen their home page which said "$25 million in research funding" and recall from their slide deck that $15m had been spent on CILI. I guess the difference came from NIH that wasn't mentioned. Salzman has an incredible ability to blow through other peoples money - like giving talent $13 million in cash. $25 million and didn't even reach a clinical endpoint. Really no point mentioning a sunk cost. I just checked their deck again, they anticipated p1 would start last August. Maybe this August?

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue